huahaipharm(SH:600521) Xin Lang Cai Jing·2025-10-13 05:23Core Viewpoint - Huahai Pharmaceutical experienced a 5.01% decline in stock price, closing at 19.73 CNY per share, with a trading volume of 487 million CNY and a turnover rate of 1.62%, resulting in a total market capitalization of 29.541 billion CNY [1] Group 1: Company Overview - Zhejiang Huahai Pharmaceutical Co., Ltd. was established on February 28, 2001, and went public on March 4, 2003 [1] - The company specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The revenue composition of the company includes finished drug sales at 61.86%, raw materials and intermediates sales at 36.75%, other revenues at 0.78%, and technical services at 0.62% [1] Group 2: Fund Holdings - Anxin Fund has one fund heavily invested in Huahai Pharmaceutical, specifically Anxin Medical Health Stock A (010709), which reduced its holdings by 250,200 shares in the second quarter, now holding 172,820 shares, representing 3.4% of the fund's net value, ranking as the ninth largest holding [2] - The estimated floating loss for the fund today is approximately 1.7973 million CNY [2] - Anxin Medical Health Stock A was established on January 12, 2021, with a current size of 444 million CNY, achieving a year-to-date return of 64.37%, ranking 201 out of 4220 in its category [2] Group 3: Fund Manager Information - The fund manager of Anxin Medical Health Stock A is Chi Chenshen, who has been in the position for 4 years and 276 days [3] - The total asset size of the fund is 946 million CNY, with the best fund return during the tenure being 56.95% and the worst being 53.28% [3]